Latest News About Wegovy

Here are the latest notable Wegovy developments up to May 2026, based on recent coverage:

• FDA progress and new formulations: Novo Nordisk has been pursuing expanded access and new formulations, including an oral/alternative dosing approach to Wegovy’s established injectable semaglutide regimen. This shift is part of a broader push to improve accessibility and adherence for weight-management therapies.

• Pricing and competition: Competition and price pressures remain significant. Reports in late 2025 and early 2026 highlighted price adjustments and ongoing scrutiny of weight-loss medications, with Eli Lilly also advancing competing therapies. These dynamics influence patient access and payer strategies.

• Regulatory and safety updates: Wegovy continues to emphasize safety information and boxed warnings, with ongoing communications about risks and appropriate patient selection. Novo Nordisk maintains a robust information program for prescribers and patients.

• Company updates: Novo Nordisk’s leadership and regulatory communications, including recent newsroom posts, provide the latest corporate context for Wegovy’s development, approvals, and strategic priorities.

What would you like to know more specifically?

• Recent FDA actions or new indications for Wegovy
• Price changes, payer policies, or patient assistance programs
• Developments of new formulations (oral/tablet versions) or dosing regimens
• Availability or access updates in your region (Buffalo, NY)